Phase II Results of Ara-C and Idarubicin in Combination with the Selective Inhibitor of Nuclear Export (SINE) Compound Selinexor (KPT-330) in Patients with Relapsed or Refractory AML

被引：8
|
作者：
Fiedler, Walter [1 ]
Heuser, Michael [2 ]
Chromik, Joerg [3 ]
Thol, Felicitas [2 ]
Bokemeyer, Carsten [4 ]
Theile, Susann [5 ]
Lebkuechner, Isabell [5 ]
Kranich, Anne L. [6 ]
机构：
[1] Univ Hosp Eppendorf, Dept Hematol & Oncol, Hamburg, Germany
[2] Hannover Med Sch, Dept Hematol Hemostasis Oncol & Stem Cell Transpl, Hannover, Germany
[3] Univ Hosp Frankfurt, Frankfurt, Germany
[4] Univ Med Ctr Hamburg Eppendorf, Ctr Oncol, Med Clin & Polyclin 2, Hamburg, Germany
[5] GSOmbH, Hamburg, Germany
[6] GSO Global B V, Amsterdam, Netherlands
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.341.341
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
341
引用
收藏
页数：6
相关论文
共 50 条
  • [1] PRELIMINARY PHASE II RESULTS OF ARA-C AND IDARUBICIN IN COMBINATION WITH SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND SELINEXOR (KPT-330) IN PATIENTS WITH RELAPSED OR REFRACTORY AML
    Fiedler, W.
    Heuser, M.
    Ottmann, O.
    Kebenko, M.
    Thol, F.
    Trummer, A.
    Brandts, C.
    Bokemeyer, C.
    Theile, S.
    Kranich, A.
    HAEMATOLOGICA, 2015, 100 : 221 - 221
  • [2] A PHASE 1 DOSE ESCALATION STUDY OF THE ORAL SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) SELINEXOR (KPT-330) IN PATIENTS (PTS) WITH RELAPSED / REFRACTORY ACUTE MYELOID LEUKEMIA (AML)
    Garzon, R.
    Flinn, I.
    Berdeja, J.
    DeAngelo, D.
    Wadleigh, M.
    Yee, K.
    Schuh, A.
    Mau-Sorensen, M.
    Brown, P.
    Lancet, J.
    Shah, B.
    Gutierrez, M.
    Gabrail, N.
    Wagner-Johnston, N.
    Blum, W.
    Carlson, R.
    Klebanov, B.
    McCauley, D.
    Shacham, E.
    McCartney, J.
    Marshall, T.
    Saint-Martin, J. R.
    Rebello, S.
    Rashal, T.
    Kauffman, M.
    Shacham, S.
    Mirza, M.
    Stone, R.
    HAEMATOLOGICA, 2014, 99 : 527 - 528
  • [3] A phase I dose-escalation study of the oral selective inhibitor of nuclear export (SINE) KPT-330 (selinexor) in patients (pts) with relapsed/refractory acute myeloid leukemia (AML).
    Yee, Karen W. L.
    Savona, Michael
    Sorensen, Morten
    Brown, Peter
    Blum, William G.
    DeAngelo, Daniel J.
    Gutierrez, Martin
    Garzon, Ramiro
    Schuh, Andre C.
    Gabrail, Nashat Y.
    Wadleigh, Martha
    Lancet, Jeffrey E.
    Shah, Bijal D.
    Berdeja, Jesus G.
    Wagner-Johnston, Nina D.
    Flinn, Ian
    Rashal, Tami
    Kauffman, Michael
    Shacham, Sharon
    Stone, Richard M.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [4] Selinexor, ARA-C and Idarubicin: An Effective and Tolerable Combination in Patients with Relapsed/Refractory AML: A Multicenter Phase II Study
    Fiedler, Walter
    Chromik, Joerg
    Kebenko, Maxim
    Thol, Felicitas
    Trummer, Arne
    Schuenemann, Chirstoph
    Brandts, Christian H.
    Koehler, Anne
    Schlipfenbacher, Vera
    Bokemeyer, Carsten
    Theile, Susann
    Kranich, Anne L.
    Heuser, Michael
    BLOOD, 2015, 126 (23)
  • [5] Selinexor (KPT-330), an oral Selective Inhibitor of Nuclear Export (SINE) compound, in combination with FOLFOX in patients with metastatic colorectal cancer (mCRC) - final results of the phase I SENTINEL trial
    Nilsson, S.
    Stein, A.
    Rolfo, C.
    Kranich, A.
    Quidde, J.
    Papadimitriou, K.
    Theile, S.
    Amberg, S.
    Bokemeyer, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 122 - 122
  • [6] Selinexor (KPT-330), an Oral Selective Inhibitor of Nuclear Export (SINE) Compound, in Combination with FOLFOX in Patients with Metastatic Colorectal Cancer (mCRC) - Final Results of the Phase I Trial SENTINEL
    Nilsson, Sven
    Stein, Alexander
    Rolfo, Christian
    Kranich, Anne L.
    Mann, Julia
    Papadimitriou, Konstantinos
    Theile, Susann
    Amberg, Stefanie
    Bokemeyer, Carsten
    CURRENT CANCER DRUG TARGETS, 2020, 20 (10) : 811 - 817
  • [7] Selective Inhibitor of Nuclear Export (SINE), Selinexor (KPT-330), Shows Remarkable Activity Against AML Leukemia-Initiating Cells
    Etchin, Julia
    Bonnie Thi Le
    Kentsis, Alex
    Mansour, Marc R.
    Berezovskaya, Alla
    Stone, Richard M.
    Galinsky, Ilene
    DeAngelo, Daniel J.
    McCauley, Dilara
    Kauffman, Michael
    Shacham, Sharon
    Wang, Jean C. Y.
    Kung, Andrew L.
    Look, A. Thomas
    BLOOD, 2014, 124 (21)
  • [8] Safety, Efficacy, and Determination of the Recommended Phase 2 Dose for the Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330)
    Chen, Christine
    Garzon, Ramiro
    Gutierrez, Martin
    Jacoby, Meagan A.
    Brown, Peter
    Flinn, Ian
    Stone, Richard M.
    Savoie, Mary Lynn
    Baz, Rachid
    Gabrail, Nashat Y.
    Wang, Michael
    Martin, Peter
    Siegel, David
    Mau-Sorensen, Morten
    Andreef, Michael
    Marshall, Tracey
    Saint-Martin, Jean-Richard
    Carlson, Robert
    Shacham, Sharon
    Kauffman, Michael
    Kuruvilla, John
    BLOOD, 2015, 126 (23)
  • [9] The Oral Selective Inhibitor of Nuclear Export ( SINE) Selinexor (KPT-330) Demonstrates Broad and Durable Clinical Activity in Relapsed / Refractory Non Hodgkin's Lymphoma (NHL)
    Kuruvilla, John
    Byrd, John C.
    Flynn, Joseph M.
    Garzon, Ramiro
    Porcu, Pierluigi
    Wagner-Johnston, Nina
    Savoie, Mary Lynn
    Stone, Richard M.
    Jacobsen, Eric D.
    Mau-Sorensen, Morten
    Brown, Peter de Nully
    Baz, Rachid
    Shal, Bijal
    Flinn, Ian
    Gabrail, Nashat
    Kukreti, Vishal
    Tiedemann, Rodger E.
    Landesman, Yosef
    Klebanov, Boris
    Shacham, Eran
    Saint-Martin, Jean-Richard
    Marshall, Tracey
    McCartney, John
    McCauley, Dilara
    Carlson, Robert
    Norori, Sasha
    Savona, Michael R.
    Rashal, Tami
    Mirza, Mansoor R.
    Kauffman, Michael
    Shacham, Sharon
    BLOOD, 2014, 124 (21)
  • [10] Preclinical Effect of Selinexor (KPT-330), a Selective Inhibitor of Nuclear Export, in Pediatric Rhabdoid Tumors
    Marks, L.
    Diolaiti, D.
    Mundi, P.
    Gaviria, E.
    Rainey, A.
    Dela Cruz, F.
    Andreas, C.
    Kung, A.
    PEDIATRIC BLOOD & CANCER, 2018, 65 : S394 - S395
12345